PMID- 34408722
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210820
IS  - 1664-2295 (Print)
IS  - 1664-2295 (Electronic)
IS  - 1664-2295 (Linking)
VI  - 12
DP  - 2021
TI  - Serum Metabolites Differentiate Amnestic Mild Cognitive Impairment From Healthy 
      Controls and Predict Early Alzheimer's Disease via Untargeted Lipidomics 
      Analysis.
PG  - 704582
LID - 10.3389/fneur.2021.704582 [doi]
LID - 704582
AB  - Background and Aim: Alzheimer's disease (AD) is the most common type of dementia 
      and presents with metabolic perturbations early in the disease process. In order 
      to explore biomarkers useful in predicting early AD, we compared serum 
      metabolites among patients suffering different stages of AD. Methods: We 
      recruited 107 participants including 23 healthy controls (HC), 21 amnestic mild 
      cognitive impairment (aMCI), 24 non-amnestic mild cognitive impairment (naMCI) 
      and 39 AD patients. Via liquid chromatography-mass spectrometry based serum 
      untargeted lipidomics analysis, we compared differences in serum lipid 
      metabolites among these patient groups and further elucidated biomarkers that 
      differentiate aMCI from HC. Results: There were significant differences of serum 
      lipid metabolites among the groups, and 20 metabolites were obtained under 
      negative ion mode from HC and aMCI comparison. Notably, 16:3 cholesteryl ester, 
      ganglioside GM3 (d18:1/9z-18:1) and neuromedin B were associated with cognition 
      and increased the predictive effect of aMCI to 0.98 as revealed by random forest 
      classifier. The prediction model composed of MoCA score, 16:3 cholesteryl ester 
      and ganglioside GM3 (d18:1/9z-18:1) had good predictive performance for aMCI. 
      Glycerophospholipid metabolism was a pathway common among HC/aMCI and aMCI/AD 
      groups. Conclusion: This study provides preliminary evidence highlighting that 
      16:3 cholesteryl ester were useful for AD disease monitoring while ganglioside 
      GM3 (d18:1/9z-18:1) and neuromedin B discriminated aMCI from HC, which can 
      probably be applied in clinic for early predicting of AD.
CI  - Copyright (c) 2021 Zhang, Li, Meng, Yu, He, Lin, Su, Hu, Liu, Liu, Luo and Peng.
FAU - Zhang, Lumi
AU  - Zhang L
AD  - Department of Neurology, First Affiliated Hospital, Zhejiang University School of 
      Medicine, Hangzhou, China.
FAU - Li, Lingxiao
AU  - Li L
AD  - Department of Neurology, First Affiliated Hospital, Zhejiang University School of 
      Medicine, Hangzhou, China.
FAU - Meng, Fanxia
AU  - Meng F
AD  - Department of Neurology, First Affiliated Hospital, Zhejiang University School of 
      Medicine, Hangzhou, China.
FAU - Yu, Jie
AU  - Yu J
AD  - Department of Neurology, First Affiliated Hospital, Zhejiang University School of 
      Medicine, Hangzhou, China.
FAU - He, Fangping
AU  - He F
AD  - Department of Neurology, First Affiliated Hospital, Zhejiang University School of 
      Medicine, Hangzhou, China.
FAU - Lin, Yajie
AU  - Lin Y
AD  - Department of Neurology, First Affiliated Hospital, Zhejiang University School of 
      Medicine, Hangzhou, China.
FAU - Su, Yujie
AU  - Su Y
AD  - Department of Neurology, First Affiliated Hospital, Zhejiang University School of 
      Medicine, Hangzhou, China.
FAU - Hu, Mengjie
AU  - Hu M
AD  - Department of Neurology, First Affiliated Hospital, Zhejiang University School of 
      Medicine, Hangzhou, China.
FAU - Liu, Xiaoyan
AU  - Liu X
AD  - Department of Neurology, First Affiliated Hospital, Zhejiang University School of 
      Medicine, Hangzhou, China.
FAU - Liu, Yang
AU  - Liu Y
AD  - Department of Neurology, Saarland University, Homburg, Germany.
FAU - Luo, Benyan
AU  - Luo B
AD  - Department of Neurology, First Affiliated Hospital, Zhejiang University School of 
      Medicine, Hangzhou, China.
FAU - Peng, Guoping
AU  - Peng G
AD  - Department of Neurology, First Affiliated Hospital, Zhejiang University School of 
      Medicine, Hangzhou, China.
LA  - eng
PT  - Journal Article
DEP - 20210802
PL  - Switzerland
TA  - Front Neurol
JT  - Frontiers in neurology
JID - 101546899
PMC - PMC8365883
OTO - NOTNLM
OT  - Alzheimer's disease
OT  - amnestic mild cognitive impairment
OT  - cholesteryl ester
OT  - ganglioside GM3
OT  - neuromedin B
OT  - serum
OT  - untargeted lipidomics
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/08/20 06:00
MHDA- 2021/08/20 06:01
PMCR- 2021/08/02
CRDT- 2021/08/19 06:40
PHST- 2021/05/03 00:00 [received]
PHST- 2021/07/05 00:00 [accepted]
PHST- 2021/08/19 06:40 [entrez]
PHST- 2021/08/20 06:00 [pubmed]
PHST- 2021/08/20 06:01 [medline]
PHST- 2021/08/02 00:00 [pmc-release]
AID - 10.3389/fneur.2021.704582 [doi]
PST - epublish
SO  - Front Neurol. 2021 Aug 2;12:704582. doi: 10.3389/fneur.2021.704582. eCollection 
      2021.